SLC5A2 and metabolic dysfunction-associated steatotic liver disease: In a randomized clinical trial (124) that targeted patients with MASLD without diabetes, the SGLT-2 inhibitor did not achieve the goal of resolving hepatic steatosis because the investigators did not specifically select to include patients with more advanced stages of MASLD.